Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4499 | high flow nasal cannula (HFNC) Wiki | 1.00 |
| drug3113 | Prone positioning (PP) Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In this first-in-humans dose escalation study, AZD7442 (AZD8895 + AZD1061) will be evaluated for safety, tolerability, pharmacokinetics, and generation of anti-drug antibodies (ADAs). The study is intended to enable future studies of AZD7442's efficacy in preventing and treating COVID-19.
Description: Safety and tolerability will be evaluated in terms of number of participants with AEs/SAEs, abnormal values of vital signs, safety laboratory parameters, 12 lead safety electrocardiogram, injection site reactions, and physical examination.
Measure: Number of participants with adverse events (AEs) and serious AEs Time: From Day 1 to up to last follow-up day (Day 361)Description: Cmax will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Observed maximum concentration (Cmax) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: Tmax will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Time to reach maximum concentration (Tmax) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: t½λz will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Terminal elimination half life, estimated as (ln2)/λz (t½λz) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: AUClast will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Area under the concentration curve from time zero to the time of last quantifiable concentration (AUClast) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: AUCinf will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Area under the concentration time curve from time zero extrapolated to infinity (AUCinf) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: Vss will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Volume of distribution at steady state (Vss) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: Vz will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Volume of distribution at terminal phase (Vz) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: CL will be assessed after IV infusion of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Systemic clearance (CL) (IV infusion) Time: From Day 1 to up to last follow-up day (Day 361)Description: Cmax will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Cmax (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: Tmax will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Tmax (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: t½λz will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: t½λz (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: AUClast will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: AUClast (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: AUCinf will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: AUCinf (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: CL/F will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Extravascular systemic clearance (CL/F) (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: F will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Bioavailability (F) (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: Vz/F will be assessed after IM injection of AZD7442 using noncompartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.
Measure: Extravascular terminal-phase volume of distribution (Vz/F) (IM injection) Time: From Day 1 to up to last follow-up day (Day 361)Description: The incidence of ADAs to AZD7442 in serum will be summarised by number and percentage of participants who are ADA positive. The ADA titer will be listed by participant at different time points.
Measure: Number and percentage of participants who are ADA positive Time: From Day 1 to up to last follow-up day (Day 361)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports